35.71
-0.58(-1.60%)
Currency In USD
| Previous Close | 36.29 |
| Open | 36.24 |
| Day High | 36.61 |
| Day Low | 35.65 |
| 52-Week High | 47.65 |
| 52-Week Low | 8.24 |
| Volume | 901,975 |
| Average Volume | 1.48M |
| Market Cap | 2.37B |
| PE | -12.23 |
| EPS | -2.92 |
| Moving Average 50 Days | 39.72 |
| Moving Average 200 Days | 25.15 |
| Change | -0.58 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $1,936.55 as of January 05, 2026 at a share price of $35.71. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 2 years ago, it would be worth $4,128.32 as of January 05, 2026 at a share price of $35.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
GlobeNewswire Inc.
Dec 12, 2025 4:00 PM GMT
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 1
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc.
Nov 07, 2025 11:10 PM GMT
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS),